Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
This article was originally published in The Pink Sheet Daily
Executive Summary
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.